Elafibranor and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Elafibranor
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body uses a liver enzyme called CYP3A4 to both create and clear the active forms of cariprazine (Vraylar). Elafibranor (Iqirvo) can speed that enzyme up. Because CYP3A4 both builds and breaks down cariprazine's active pieces, speeding it up could shift your levels in a way that isn't easy to predict, which is why this combo isn't recommended.
The good news is that this is a theoretical concern, meaning it hasn't been studied directly. Your care team can manage it by watching how you're doing and adjusting your plan if needed. Please don't stop either medication on your own, just check in with your pharmacist or doctor.
Mechanism: Cariprazine is a CYP3A4 substrate; CYP3A4 governs both formation and elimination of its active metabolites (desmethyl- and didesmethyl-cariprazine). Elafibranor is a CYP3A4 inducer.
Direction/magnitude: Because the same enzyme both activates and clears cariprazine, the net effect of induction on total active-moiety exposure is unpredictable and has not been quantified.
- Onset: unspecified (induction typically develops over days to weeks)
- Evidence: theoretical
- Management: Coadministration is not recommended. If unavoidable, monitor closely for altered efficacy or tolerability; dose may need individualization by the care team.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Using cariprazine (a substrate of CYP3A4) together with a CYP3A4 inducer is not advised. The active metabolites of cariprazine are both formed and cleared through CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because this combination is generally not recommended, they may consider whether an alternative to one of the drugs is appropriate.
- If both are used together, they may monitor you more closely for any change in how well your cariprazine is working or any new side effects.
- Your cariprazine dose may need to be adjusted and individualized by your care team.
What you should do: Keep taking both exactly as prescribed unless told otherwise, and let your pharmacist or prescriber know you are on both so they can guide the plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Elafibranor and Cariprazine together?
Combining cariprazine with elafibranor is not recommended because elafibranor can speed up the enzyme that both makes and clears cariprazine's active forms, so its effect is unpredictable; talk with your pharmacist or doctor before changing anything. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Elafibranor and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Elafibranor and Cariprazine interaction managed?
What your care team may do: Because this combination is generally not recommended, they may consider whether an alternative to one of the drugs is appropriate. If both are used together, they may monitor you more closely for any change in how well your cariprazine is working or any new side effects. Your cariprazine dose may need to be adjusted and individualized by your care team. What you should… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Elafibranor or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Cariprazine
Keep reading about Elafibranor
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist